International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas

Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with minimal bone marrow (BM) infiltration (<10% clonal plasma cells by immunohistochemistry) and no evidence of systemic involvement or myeloma defining events. Approximately 50% of SPs will progress to symptomatic myeloma within 5 years after initial definitive local radiotherapy. Increased availability of improved diagnostic and monitoring tools has increased the sensitivity of detection of additional lesions and marrow involvement and has implications for the follow-up strategy after treatment. Thus, the definitions and requirements for the diagnosis and follow-up of SPs are evolving. The diagnosis of SP requires the careful exclusion of multiple myeloma (MM) that would require systemic therapy, by using all the available methods to detect systemic disease (advanced imaging, sensitive BM assessment methods, blood and urine tests). Local radiotherapy remains the mainstay of therapy, and despite the availability of innovative drugs for MM, the clinical benefit of systemic therapy currently remains poorly defined. The International Myeloma Working Group provides here updated recommendations for the diagnosis, evaluation, treatment, and response assessment of patients with SPs, incorporating recent data and advances in diagnostic tools.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-07-22
DOI
https://doi.org/10.1200/jco-26-00410
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas

Sigurður Y. Kristinsson, Luciano J. Costa, Saad Z. Usmani, Efstathios Kastritis et al.
Journal of Clinical Oncology
Multiple Myeloma Research and Treatments
article

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas

Sigurður Y. Kristinsson, Luciano J. Costa, Saad Z. Usmani, Efstathios Kastritis, Jesús F. San Miguel, Leo Rasche, Shaji Kunnathu Kumar, Heinz Ludwig, T Martin, María‐Victoria Mateos, Joshua Ryan Richter, Meletios Α. Dimopoulos, Salomon Manier, Eirini Katodritou, Nikhil C. Munshi, Hira S. Mian, Douglas W. Sborov, Elena Zamagni, Bruno Paiva, Joseph Mıkhael, Philip L. McCarthy, Wee Joo Chng, S. Vincent Rajkumar, Jens Hillengaß, Charlotte Pawlyn, Philippe Moreau, Vania Tietsche de Moraes Hungria, K. Elias, Sagar Lonial, Dragan Jevremovic, Monika Engelhardt, Wilson Gonsalves
article en

Abstract

Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with minimal bone marrow (BM) infiltration (<10% clonal plasma cells by immunohistochemistry) and no evidence of systemic involvement or myeloma defining events. Approximately 50% of SPs will progress to symptomatic myeloma within 5 years after initial definitive local radiotherapy. Increased availability of improved diagnostic and monitoring tools has increased the sensitivity of detection of additional lesions and marrow involvement and has implications for the follow-up strategy after treatment. Thus, the definitions and requirements for the diagnosis and follow-up of SPs are evolving. The diagnosis of SP requires the careful exclusion of multiple myeloma (MM) that would require systemic therapy, by using all the available methods to detect systemic disease (advanced imaging, sensitive BM assessment methods, blood and urine tests). Local radiotherapy remains the mainstay of therapy, and despite the availability of innovative drugs for MM, the clinical benefit of systemic therapy currently remains poorly defined. The International Myeloma Working Group provides here updated recommendations for the diagnosis, evaluation, treatment, and response assessment of patients with SPs, incorporating recent data and advances in diagnostic tools.

Journal of Clinical Oncology
Translational Genomics Research Institute (US), Roswell Park Comprehensive Cancer Center (US), Royal Marsden NHS Foundation Trust (GB), Memorial Sloan Kettering Cancer Center (US), Harvard University (US), Institute of Cancer Research (GB), Emory University (US), University of Freiburg (DE), University of Iceland (IS), University of California, San Francisco (US), Korea University (KR), National and Kapodistrian University of Athens (GR), University of Utah (US), Heidelberg University (DE), Huntsman Cancer Institute (US), University Medical Center Freiburg (DE), VA Boston Healthcare System (US), University Hospital Heidelberg (DE), Centre Hospitalier Universitaire de Lille (FR), Centre Hospitalier Universitaire de Nantes (FR), University of Alabama at Birmingham (US), Theageneio General Hospital (GR), Lille’s Cardiology Hospital (FR), National University Cancer Institute, Singapore (SG), São Germano Oncologia (BR), Dana-Farber Cancer Institute (US), Istituto di Ematologia di Bologna (IT), Mayo Clinic in Arizona (US), Universitätsklinikum Würzburg (DE), Instituto de Investigación Biomédica de Salamanca (ES), Clinica Universidad de Navarra (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), UCSF Helen Diller Family Comprehensive Cancer Center (US), University of Bologna (IT), Nantes Université (FR), McMaster University (CA), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 9%
Multiple Myeloma Research and Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.